OneTar Biomedicine
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- Undisclosed
Investors
- 3
About OneTar Biomedicine
, trading as OneTar Biomedicine, focuses on developing cutting-edge biopharmaceutical solutions. OneTar Biomedicine's primary offerings include a range of biopharmaceutical products designed to address various health conditions. The company develops novel therapeutics with a focus on improving treatment efficacy and patient safety. Their product pipeline aims to cater to the needs of healthcare providers and patients, facilitating better health outcomes across diverse medical fields. The company generates revenue through various models, offering subscription-based services and commercial support for its biopharmaceutical products. Clients typically engage in contracts structured around annual agreements, ensuring access to premium features, dedicated support, and the latest therapeutic solutions tailored for their specific needs.
Who invested in OneTar Biomedicine
3 investors across 2 rounds
See all investors in OneTar Biomedicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OneTar Biomedicine
Who invested in OneTar Biomedicine?
OneTar Biomedicine has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OneTar Biomedicine raised?
OneTar Biomedicine has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did OneTar Biomedicine last raise money?
OneTar Biomedicine's most recent round on record is a Series A, in Jan 2026.
What does OneTar Biomedicine do?
, trading as OneTar Biomedicine, focuses on developing cutting-edge biopharmaceutical solutions.
Where is OneTar Biomedicine headquartered?
OneTar Biomedicine is headquartered in Shanghai, China.
Which VCs invest in companies like OneTar Biomedicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at OneTar Biomedicine's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like OneTar Biomedicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.